Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial-Reference-Cited by-同舟云学术

Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial

Published:2016-06-02 Issue:11 Volume:231 Page:2541-2547
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J. Cell. Physiol.

Author:

Pizzuti Laura¹,Barba Maddalena¹²,Giannarelli Diana³,Sergi Domenico¹,Botti Claudio⁴,Marchetti Paolo⁵,Anzà Michele⁴,Maugeri‐Saccà Marcello¹²,Natoli Clara⁶,Di Filippo Simona⁷,Catenaro Teresa¹,Tomao Federica⁸,Amodio Antonella¹,Carpano Silvia¹,Perracchio Letizia⁹,Mottolese Marcella⁹,Di Lauro Luigi¹,Sanguineti Giuseppe¹⁰,Di Benedetto Anna⁹,Giordano Antonio¹¹,Vici Patrizia¹

Affiliation:

1. Division of Medical Oncology 2Regina Elena National Cancer InstituteRomeItaly

2. Scientific DirectionRegina Elena National Cancer InstituteRomeItaly

3. Biostatistics UnitRegina Elena National Cancer InstituteRomeItaly

4. Department of SurgeryRegina Elena National Cancer InstituteRomeItaly

5. Oncology Unit, Sant'Andrea HospitalLa Sapienza University of RomeRomeItaly

6. Department of Medical, Oral and Biotechnological Sciences and CeSI‐MeTG. d'Annunzio UniversityChietiItaly

7. Santa Maria GorettiHospital of LatinaLatinaItaly

8. Department of Gynecologic OncologyUniversity “Sapienza”RomeItaly

9. Department of PathologyRegina Elena National Cancer InstituteRomeItaly

10. Department of Radiation OncologyRegina Elena National Cancer InstituteRomeItaly

11. Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, College of Science and TechnologyTemple UniversityPhiladelphiaPennsylvania

Funder

Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO)

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.25432

Reference39 articles.

1. Sample size tables for exact single-stage phase II designs

2. Recombinant humanized anti‐HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts;Baselga J;Cancer Res,1998

3. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

4. Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

5. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Strategies Using Sagacious Targeting for Site-Specific Drug Delivery in Breast Cancer Treatment: Clinical Potential and Applications;Critical Reviews™ in Therapeutic Drug Carrier Systems;2024

2. Preventing effect of astragalus polysaccharide on cardiotoxicity induced by chemotherapy of epirubicin: A pilot study;Medicine;2022-08-12

3. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells;Chemico-Biological Interactions;2021-05

4. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review;PLOS ONE;2021-04-16

5. Update on systemic treatment for newly diagnosed inflammatory breast cancer;Journal of Advanced Research;2021-03